The U.S. scar treatment market size is expected to reach $11.3 billion by 2023. The market is mainly driven by increasing number of surgeries for the improvement of physical appearance, growing prevalence of skin problems leading to scar formation, increasing expenditure on personal care, and technological advancements in dermatological products.
Get report sample at@ http://bit.ly/2N5Qc9n
On the basis of end user, the scar treatment market is categorized into home-use, hospitals, dermatology clinics, and others. During the forecast period, the market is expected to witness the fastest growth in hospitals end-user category, with CAGR of 11.2%. This growth is mainly characterized by technological advancements in the laser-based products for the treatment of scars, increasing adoption of these products by the surgeons, and rising number of surgical procedures performed in the U.S. hospitals.
The key players operating in the U.S. scar treatment industry are launching various topical products that are intended to be used at-home by the users. For instance, in April 2018, Sonoma Pharmaceuticals Inc. received approval from the United States Food and Drugs Administration (USFDA) for an antimicrobial post-therapy gel. It used to manage post-non-ablative laser therapy procedures and post-microdermabrasion therapy as well for superficial chemical peels. The product can also be used to relieve itch and pain from minor skin related problems.
Some of the other key players operating in the U.S. scar treatment market are Revitol Corporation Inc., CCA Industries Inc., Scarguard Labs LLC, Quantum Health, Valeant Pharmaceuticals International Inc., Pacific World Corporation, Merz Pharma GmbH & Co. KGaA, and Johnson & Johnson.
Source: P&S Intelligence
留言列表
